Gilteritinib was recently approved in Japan and the United States based on findings from a phase 3 study (NCT02421939), which demonstrated the clinical benefit of gilteritinib compared with salvage chemotherapy in patients with FLT3 mutation-positive R/R AML [22, 23]. Here, FLT3 is linked to acute myeloid leukemia.